Unlisted is building a global ownership platform for unlisted companies and investors. As of now we are companies succeed with employee stock ownership plans, raising capital and ownership management. We are a purpose driven company. Our long term goal and vision is to democratise entrepreneurship and wealth creation. We are achieving that by building providing entrepreneurs with tools which makes it easer for them to succeed. And we are allowing more people get access to equity and be part of the big value creation in the unlisted market.

CL-Invest is an investment company based in Oslo, Norway with a team of experts with decades of experience in project finance, assessment, and development. ​We work in partnership with National Oil Companies (NOCs) and independent oil producers to realize scalable emission reductions that can be achieved rapidly. Our mission is immediate climate action through the elimination of financial barriers with a focus on methane and flare reduction projects in emerging economies. CL-invest is presently developing several methane and flare abatement projects in Nigeria and Azerbaijan with current expansion into Iraq, Venezuela, Turkmenistan, Uzbekistan, Oman, and Iran among other countries underway. CL-Invest offers a full-service solution including project identification and assessment, project financing, implementation, verification and monitoring as well as High-Quality carbon credit development and sales. We leverage strong international partners to help manage all activities of this project cycle. The company was founded through a de-merger of Carbon Limits AS in 2021 whereby CL-Invest now subcontracts Carbon Limits to provide technical advisory and consulting services to CL-Invest and indirectly to its clients. To date, our total impact equates to 9.2 million tons of CO2e removed and approximately 70 million euros of carbon credit finance generated. Between 2022 and 2030, CL-Invest plans to initiate more than 200 projects and achieve a total carbon emission reduction equivalent to 61.4 million tCO2e. Annual estimated emission reductions on our existing projects are ​800 000 tCO2e in 2022 and 1 million tCO2e in 2023. CL-Invest is currently in the process of establishing strategic partnerships with international players who have complementary expertise and resources to assist the company in ensuring a rapid upscaling of the business. We are in the final stages of securing outside investment capital from major industry players to support our growth trajectory to be publicly announced shortly. Hence, we are now in search of a Chief Development Officer - Carbon Credits who can aid us and be the driving force in our rapid expansion.

Founded in 2018 by Bård Anders and Stig Olav Kasin, PortalOne is the world’s first hybrid games platform. Hybrid games are a new category of entertainment that seamlessly mix games with live shows that are embedded directly inside the games. This mobile-first content gives users a more engaging games experience, with stunning visuals and enhanced interactivity while allowing users to compete for prizes. We enrich everyday life by providing captivating, positive entertainment — with rewarding interactions that transform virtual wins into real-world rewards. PortalOne is US-based with a subsidiary in Oslo, Norway Hybrid Games are a whole new category of unique gaming entertainment. We harness the power of the Unreal Engine and other technologies to create unique content with stunning visuals and interactivity.We have global financial backing and global partners.

Cavai AS was founded in December 2017 with the goal of revolutionizing online advertising. User experiences have largely been neglected on the web, and Cavai saw early on that chatbot technology, which has initially been used in customer service, could be a wonderfully good advertising product. Usually, chatbot technology is used as customer service on its own website, while Cavai's platform is built to be able to use chatbot technology on millions of websites for contextual advertising. The team today consists of 15 people, and the product has been launched in Norway, Finland, Sweden and the UK with 50 paying customers. Customers are very pleased and report that Cavai's technology is having a very good effect on completed advertising campaigns. Cavai will have its first month of positive operating results in October and looks to have sales of around 3 million in 2019. Next year will be a big growth year, where we have budgeted with a turnover of NOK 41 million. This growth has also been discussed by Finansavisen, where as part of Finansavisen's web-TV series "Vext", Cavai filmed his meeting with advertising legend Sir Marting Sorell in London. For more information, see https://finansavisen.no/vext/tech/2019/10/23/7465643/chatbot-company-cavai-2020-blir-the-store-growst>  To finance further growth, we are now running a seed funding round of NOK 9.5 - 15 million. The company is priced at NOK 60 million pre-money. For more information see the investor summary, investor presentation and subscription form attached.

TracSense develops intelligent automotive solutions for the next-generation cars. Primarily the company develops and optical sensor system that can recognize slippery roads. The company's mission is to make autonomous driving possible under all weather conditions. TracSense is an ambitious start-up with its headquarters in Oslo, Norway. Have a look at our website tracsen.se/careers for our current job openings!

Monio AS (org. nr. 913 978 617) er et heleid datterselskap av SpareBank 1 SR-Bank ASA (org. nr. 937 895 321). Monio AS formidler lån til små og mellomstore bedrifter og er regulert av Finanstilsynet med tillatelse til å drive virksomhet som betalingsforetak og er registrert som låneformidler. Som lånformidler er Monio ikke en part i låneavtalen mellom långiver og låntaker.

EpiGuard AS is an innovative Norwegian Medical Technology Company established in 2015 by a group of doctors at the Oslo University Hospital (OUS) together with co-founders Inven2, Eker Group AS, and Hansen Protection AS. EpiGuard has evolved into a highly skilled knowledge-based company. The business model is to develop and manufacture high-end medical equipment for the safe transport of contagious patients. The products will be distributed globally through strategic partners. Currently, the main product is the medical isolation and transportation system, EpiShuttle. The system is developed by clinical experts at OUS, with first-hand experience in providing advanced treatment and transportation of patients with highly infectious diseases, such as Ebola.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Preventing One Million Falls Before 2024 Dele Health Tech is redefining how the market conceptualizes and achieves fall prevention by offering a data fusion platform that functions as middleware between hardware and data stream partners. Our mission: To save lives through fall prevention, and prevent one million falls by 2024.

Antibiotic resistance and bacterial infections are a large threat to modern healthcare. The Norwegian company SoftOx Solutions has developed a patented technology with the potential of becoming a game changer in fighting infections. To achieve this SoftOx has a highly competent organization and established a long-term relationship with leading scientists from the University of Copenhagen and Excite International, Canada. SoftOx wound cleansing solution shall become the first antiseptic with solid clinical evidence of infection removal in chronic wounds, giving us a unique market position in a 90 billion NOK wound care market.

Lawbotics has developed an innovative tool called LEXOLVE to streamline parts of the legal processes that take place in all companies – namely the creation of legal contracts and other documents. By letting legal experts automate their own legal documents using our software, we make it easy for businesses to increase the quality of their legal documents while saving a significant amount of time and resources.

Fieldnode AS is a software company that specializes in building technology to facilitate the digital transformation of supply chains. Founded in 2020 by Christian Duun Norberg, as a spin-off from Fieldmade AS, our mission is to transform the costly and unsustainable process of holding large physical warehouses into a streamlined and efficient digital inventory system. By providing a cutting-edge technology platform, we enable on-demand small volume production and network manufacturing while eliminating the need for physical inventories. Our focus is on collaborating with leading entities and key stakeholders within the Energy sector to take the leading position in digital inventory technology.

DoMore Diagnostics is on a mission to transform cancer diagnostics with artificial intelligence to improve patient care and make drug development more effective. We use state-of-the-art methods to improve patients’ quality of life and help clinicians make more informed decisions. Our technology is based on pioneering research on utilizing artificial intelligence to increase the prognostic value from routine clinical pathology cancer tissue samples. The extensive research conducted at top universities (University in Oslo, Oxford University and University College of London) has been published in leading and high impact scientific journals such as The Lancet and Nature Reviews Cancer. These new methods have resulted in fully automated histotyping that provide objective and precise prognostic information that correlate and out-perform existing markers. This novel histotyping can guide selection of therapy to avoid over- and undertreatment. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, which is the fundament for precision medicine. Artificial intelligence is set for a breakthrough in medicine and several megatrends are pushing for new solutions in cancer diagnostics. Digital pathology and new AI algorithms will play a significant role in the future of medicine and hold multiple commercial opportunities. DoMore Diagnostics is at the forefront of the field and will bring these next generation products to the clinic.

Alpha Studio is a committed digital agency with great passion and ambition for what we do. We help companies with building a brand, changing perspective, influencing and creating results and realizing dreams. We have a network of skilled designers, copywriters and marketers both in Norway and abroad, that way we can adapt to your needs. We are currently working on developing a platform Called "Influencer Studio"- a platform by Alpha Studio. The Influencer Studio will be a platform where small and medium size brands can find influencers to work with. The reason the brands will choose us is that we are a marketing agency and not only a platform, we can provide full marketing services. We will also have the lowest prices in the market.

The Curated is an online dtc fashion label focusing on sustainable luxury for the modern woman. We work with left over fabrics, certified suppliers and ethically audited factories to create limited runs of classic staples. We have an honest pricing policy in order to make luxury quality affordable.